Milvia Zambetti

S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome.

Lajos Pusztai, Catherine M. Kelly, Takayuki Iwamoto, 2011 .

Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.

G. Bonadonna, L. Gianni, P. Valagussa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

Paolo Morandi, Ana Lluch, Patricia Gomez, 2012, Breast Cancer Research and Treatment.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

Roman Rouzier, Lajos Pusztai, J. Ross, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence

Elia Biganzoli, Patrizia Boracchi, Danila Coradini, 2010, Cancer science.

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Anton Belousov, Wolfgang Eiermann, M. Cheang, 2014, Clinical Cancer Research.